Curated News
By: NewsRamp Editorial Staff
August 27, 2025
Cancer Nerves Found to Cause Immunotherapy Resistance in Surprising Discovery
TLDR
- Researchers discovered cancer-induced nerve damage causes immunotherapy resistance, offering new targets for companies like Calidi Biotherapeutics to develop competitive treatments.
- A joint team from MD Anderson, Karolinska Institutet, and Moffitt Cancer Center identified nerve damage as the mechanism behind resistance to cancer immunotherapy.
- This discovery of nerve damage causing immunotherapy resistance could lead to more effective cancer treatments and improved patient outcomes worldwide.
- Scientists found an unexpected link between cancer-induced nerve damage and immunotherapy resistance, opening new research pathways in oncology.
Impact - Why it Matters
This discovery matters because immunotherapy has become a cornerstone of modern cancer treatment, offering hope to millions of patients worldwide. However, treatment resistance remains a major challenge, causing many therapies to fail and leading to poor outcomes. Understanding that cancer can damage adjacent nerves to create resistance provides crucial insight that could lead to new combination therapies, potentially saving countless lives and improving treatment success rates. For cancer patients and their families, this research represents hope for more effective treatments and better survival outcomes in the future.
Summary
A groundbreaking discovery by researchers from the University of Texas MD Anderson Cancer Center, Karolinska Institutet, and Moffitt Cancer Center has revealed an unexpected mechanism behind resistance to cancer immunotherapy: cancer-induced damage to adjacent nerves. This surprising finding challenges conventional understanding of why some patients fail to respond to cutting-edge immunotherapies that have revolutionized cancer treatment in recent years.
The research highlights how tumors can manipulate their local environment, specifically targeting nearby nerves to create resistance pathways. This discovery opens new avenues for developing combination therapies that could overcome treatment resistance. Companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI), which are actively working on innovative cancer treatments, may find this research particularly valuable as they develop next-generation immunotherapies that address these newly identified resistance mechanisms.
The study was featured on TinyGems, a specialized communications platform focused on innovative small-cap and mid-cap companies with significant growth potential. As part of the Dynamic Brand Portfolio at IBN, TinyGems provides comprehensive corporate communications solutions including press distribution through InvestorWire, editorial syndication to over 5,000 outlets, and enhanced social media distribution to millions of followers, ensuring that breakthrough research like this reaches investors, medical professionals, and the general public effectively.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Cancer Nerves Found to Cause Immunotherapy Resistance in Surprising Discovery
